Хронический небактериальный остеомиелит: опыт одного Центра

аутовоспалительные синдромы, хронический небактериальный остеомиелит, хронический рецидивирующий мультифокальный остеомиелит, бисфосфонаты, ингибиторы фактора некроза опухоли-альфа, дети

1. Wipff J., Costantino F., Lemelle I., et al. A large national cohort of French patients with chronic recurrent multifocal osteitis. Arthritis Rheumato 2015; l67: 1128–37.

2. Stern S.M., Ferguson P.J. Autoinflammatory bone diseases. Rheum Dis Clin North Am 2013; 39: 735–49.

3. Borzutzky A., Stern S., Reiff A., Zurakowski D., Steinberg E.A.,Dedeoglu F., et al. Pediatric chronic nonbacterial osteomyelitis. Pediatrics 2012; 130: e1190–7.

4. Sato H., Wada Y., Hasegawa E., Nozawa Y., Nakatsue T., Ito T., et al. Adult-onset Chronic Recurrent Multifocal Osteomyelitis with High Intensity of Muscles Detected by Magnetic Resonance Imaging, Successfully Controlled with Tocilizumab. Intern Med 2017; 56: 2353–60.

5. Giedion A., Holthusen W., Masel L.F., Vischer D. Subacute and chronic “symmetrical” osteomyelitis. Ann Radiol (Paris) 1972; 15: 329–2.

6. Hofmann S.R., Kapplusch F., Girschick H.J., Morbach H., Schnabel A., Rosen-Wolff A., et al. Chronic Recurrent Multifocal Osteomyelitis (CRMO): Presentation, Pathogenesis, and Treatment. Curr Osteoporos Rep 2017; 15: 542–54.

7. Копчак О.Л., Костик М.М., Мушкин А.Ю. Хронический небактериальный («стерильный») остеомиелит в практике детского ревматолога, современные подходы к диагностике и лечению: обзор литературы и анализ собственных данных. Вопросы современной педиатрии 2016; 15 (1): 33–44.

8. Valdearcos M., Esquinas E., Meana C., Pena L., Gil-de-Gomez L., Balsinde J., et al. Lipin-2 reduces proinflammatory signaling induced by saturated fatty acids in macrophages. J Biol Chem 2012; 287: 10894–904.

9. Ferguson P.J. Current Understating of the Pathogenesis and Management of Chronic Reccurent Multifocal Osteomyelitis. Curr Reumatol Rep 2012; 14 (2): 130–41.

10. Herlin T., Fiirgaard B., Bjerre M., Kerndrup G., Hasle H., Bing X., et al. Efficacy of anti-IL-1 treatment in Majeed syndrome. Ann Rheum Dis 2013; 72: 410–3.

11. Omenetti A., Carta S., Caorsi R., Finetti M., Marotto D., Lattanzi B., et al. Disease activity accounts for long-term efficacy of IL-1 blockers in pyogenic sterile arthritis pyoderma gangrenosum and severe acne syndrome. Rheumatology (Oxford) 2016;55:1325–35.

12. Holzinger D., Fassl S.K., de Jager W., Lohse P., Röhrig U.F., et al. Single amino acid charge switch defines clinically distinct proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1)- associated inflammatory diseases. J Allergy Clin Immunol 2015; 136 (5): 1337–45.

13. Yoshitaka T., Ishida S., Mukai T., Kittaka M., Reichenberger E.J., Ueki Y. Etanercept administration to neonatal SH3BP2 knock in cherubism mice prevents TNFinduced inflammation and bone loss. J Bone Miner Res 2014; 29 (5): 1170–82.

14. Ferguson P.J., El-Shanti H.I. Autoinflammatory bone disorders. Curr Opin Rheumatol 2007;19 (5): 492–8.

15. Shoham N.G., Centola M., Mansfield E., Hull K.M., Wood G., Wise C.A., Kastner D.L. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A 2003; 100 (23): 13501–6. DOI: 10.1073/ pnas.2135380100

16. Masters S.L., Simon A., Aksentijevich I., Kastner D.L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Ann Rev Immunol 2009; 27: 621–68. DOI: 10.1146/annurev.immunol.25.022106.141627

17. Hedrich C.M., Hahn G., Girschick H.J., Morbach H. A clinical and pathomechanistic profile of chronic nonbacterial osteomyelitis/chronic recurrent multifocal osteomyelitis and challenges facing the field. Expert Rev Clin Immunol 2013; 9 (9): 845–4. DOI: 10.1586/1744666X.2013.824670

18. Khan M.A., Osborne N.J., Anaspure R., Ramanan A.V. Clavicular swelling-classic presentation of chronic non-bacterial osteomyelitis. Arch Dis Child 2012; 98: 238. DOI: 10.1136/archdischild-2012-303187

19. Mandell G.A., Contreras S.J., Conard K., et al. Bone scintigraphy in the detection of chronic recurrent multifocal osteomyelitis. J Nucl Med. 1998;39:1778–3.

20. Шаяхметова Р.У., Сигидин Я.А., Кузьмина Н.Н., Смирнов А.В. Хронический рецидивирующий мультифокальный остеомиелит в практике ревматолога (семейные наблюдения). Научно-практическая ревматология 2015; 53 (5): 568–72.

21. Khanna G., Sato T.S., Ferguson P. Imaging of chronic recurrent multifocal osteomyelitis. Radiographics 2009; 29: 1159–7.

22. Hofmann S.R., Kapplusch F., Girschick H.J., Morbach H., Pablik J., Ferguson P.J., et al. Chronic Recurrent Multifocal Osteomyelitis (CRMO): Presentation, Pathogenesis, and Treatment. Curr Osteoporos Rep (2017) 15:542–54.

23. Hamel J., Paul D., Gahr M., Hedrich C.M. Pilot study: possible association of IL10 promoter polymorphisms with CRMO. Rheumatol Int 2012; 32: 555–6.

24. Hofmann S.R., Kubasch A.S., Ioannidis C., Rosen-Wolff A., Girschick H.J., Morbach H., et al. Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1beta expression and release. Clin Immunol 2015; 161: 300–7.

25. Hofmann S.R., Morbach H., Schwarz T., Rosen-Wolff A., Girschick H.J., Hedrich C.M. Attenuated TLR4/MAPK signaling in monocytes from patients with CRMO results in impaired IL-10 expression. Clin Immunol 2012; 145: 69–76.

26. Hofmann S.R., Schwarz T., Moller J.C., Morbach H., Schnabel A., Rosen-Wolff A., et al. Chronic non-bacterial osteomyelitis is associated with impaired Sp1 signaling, reduced IL10 promoter phosphorylation, and reduced myeloid IL-10 expression. Clin Immunol 2011; 141: 317–27.

27. Hofmann S.R., Morbach H., Schwarz T., Rosen-Wolff A., Girschick H.J., Hedrich C.M. Attenuated TLR4/MAPK signaling in monocytes from patients with CRMO results in impaired IL-10 expression. Clin Immunol 2012; 145: 69–76.

28. Hofmann S.R., Schwarz T., Moller J.C., Morbach H., Schnabel A., Rosen-Wolff A., et al. Chronic non-bacterial osteomyelitis is associated with impaired Sp1 signaling, reduced IL10 promoter phosphorylation, and reduced myeloid IL-10 expression. Clin Immunol 2011; 141: 317–27.

29. Hofmann S.R., Kapplusch F., Girschick H.J., Morbach H., Pablik J., Ferguson P.J., et al. Chronic Recurrent Multifocal Osteomyelitis (CRMO): Presentation, Pathogenesis, and Treatment. Curr Osteoporos Rep 2017; 15: 542–54.

30. Valdearcos M., Esquinas E., Meana C., Pena L., Gil-de-Gomez L., Balsinde J., et al. Lipin-2 reduces proinflammatory signaling induced by saturated fatty acids in macrophages. J Biol Chem 2012; 287: 10894–904.

31. Ferguson PJ. Current Understating of the Pathogenesis and Management of Chronic Reccurent Multifocal Osteomyelitis. Curr Reumatol Rep 2012; 14 (2): 130–41.

32. Herlin T., Fiirgaard B., Bjerre M., Kerndrup G., Hasle H., Bing X., et al. Efficacy of anti-IL-1 treatment in Majeed syndrome. Ann Rheum Dis 2013; 72: 410–3.

33. Jansson A., Renner E.D., Ramer J., Haban M., Meindl A., Grote V. et al. Classification of nonbacterial osteitis: retrospective study of clinical, immunological and genetic aspects in 89 patients. Rheumatology (Oxford) 2007; 46: 154–60.

34. Pastore S., Ferrara G., Monasta L., Meini A., Cattalini M., Martino S., et al. Chronic nonbacterial osteomyelitis may be associated with renal disease and bisphosphonates are a good option for the majority of patients. Acta Paediatr 2016; 105 (7): e328–33. DOI: 10.1111/apa.13420

35. Catalano-Pons C., Comte A., Wipff J., Quartier P., Faye A., Gendrel D., et al. Clinical outcome in children with chronic recurrent multifocal osteomyelitis. Rheumatology 2008; 47: 1397–9.

36. Teixeira S.R., Elias Junior J., Nogueira-Barbosa M.H., Guimaraes M.D., Marchiori E., Santos M.K. Whole body magnetic resonance imaging in children: state of the art. Radiol Bras 2015; 48 (2): 111–20.

37. Colmenero J.D., Ruiz-Mesa J.D., Sanjuan-Simenez R., Sobrino B., Morata P. Establishing the diagnosis of tuberculosus vertebral osteomyelitis. Eur spine J 2013; 22 (suppl 4): S579–86

38. Girschick H.J., Zimmer C., Klaus G., Darge K., Dick A., Morbach H. Chronic recurrent multifocal osteomyelitis: what is it and how should it be treated? Nat Clin Pract Rheumatol 2007; 3 (12): 733–8.

39. Santra G., Sarkar R.N., Phaujdar S., Banerjee S., Siddhanta S. Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial. Singapore Med J 2010; 51 (11): 883–7.

40. Zhao Y., Wu E., Oliver M., Cooper A., Basiaga M.L., Vora S.S., et al. Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or with Active Spinal Lesions. Arthritis Care Res (Hoboken) 2018; 70 (8): 1228–37. DOI: 10.1002/acr.23462